EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis

Hayoung Choi iD, Kyungdo Han, Jin Hyung Jung, Anthony De Soyza, Hyungjin Kim, Dong Wook Shin, Hyun Lee iD

Therapeutic Advances in Respiratory Disease · 2025-08 · 19

DOI: 10.1177/17534666251360071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 05.08.2025. Verfasst von Hayoung Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym …. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Bronchiectasis, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Comorbid rheumatoid arthritis (RA) is known to be associated with excess mortality in patients with bronchiectasis. However, whether excess mortality is affected by RA seropositivity and is altered by using disease-modifying anti-rheumatic drugs (DMARDs) remains unknown.

Objectives

To assess the association between comorbid RA and mortality in participants with bronchiectasis, plus the impacts of seropositivity and DMARDs on this association.

Design

A retrospective cohort study.

Methods

Mortality rates were compared between participants with bronchiectasis-RA overlap syndrome (BROS) ( n = 3355; 2632 seropositive RA (SPRA) and 723 seronegative RA (SNRA)) and 1:5 age- and sex-matched participants with bronchiectasis only ( n = 16,240) who were enrolled between 2010 and 2017 in the Korean National Health Insurance Service database. The participants were followed up from 1 year after RA diagnosis or the corresponding index date to the date of death, censored date, or 31 December 2020.

Results

During a median follow-up of 5.8 years (interquartile range, 4.2–7.8 years), participants with BROS revealed a 2.09-fold higher mortality risk compared with participants with bronchiectasis only, even after adjusting for potential confounders (95% confidence interval (CI), 1.88–2.33). In an analysis of RA serologic status using a fully adjusted model, participants with SPRA and those with SNRA showed 2.34-fold (95% CI, 2.09–2.62) and 1.29-fold (95% CI, 1.01–1.65) increased risks, respectively, than participants with bronchiectasis only. DMARDs use was related to increased mortality.

Conclusion

The presence of RA doubles the mortality risk in patients with bronchiectasis. Increased mortality risk was more evident in patients with SPRA and those who use DMARDs. Causality cannot be ascertained, but these data suggest that rheumatic inflammation may affect disease progression and excess mortality in patients with BROS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBronchiectasisAntirheumatic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedRepublic of KoreaRisk FactorsComorbidityRisk AssessmentDatabases, FactualAdultTime Factors

Stichwörter der Autor:innen

bronchiectasisepidemiologyinflammationmortalityrheumatoid arthritis

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.
  • Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
  • Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Population and Health Science Institute, National Institute of Health Research Biomedical Research Centre, Newcastle University, Newcastle, UK.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Hayoung Choi, Hyun Lee

Förderung

  • Ministry of Education

Zitieren

APA

Choi, H., Han, K., Jung, J. H., De Soyza, A., Kim, H., Shin, D. W., & Lee, H. (2025). Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251360071

Vancouver

Choi H, Han K, Jung JH, De Soyza A, Kim H, Shin DW, et al. Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251360071

BibTeX
@article{Choi2025,
  author = {Choi, Hayoung and Han, Kyungdo and Jung, Jin Hyung and De Soyza, Anthony and Kim, Hyungjin and Shin, Dong Wook and Lee, Hyun},
  title = {Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  volume = {19},
  doi = {10.1177/17534666251360071}
}
Kostenlos starten →